Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5283173 A
Publication typeGrant
Application numberUS 07/469,285
Publication dateFeb 1, 1994
Filing dateJan 24, 1990
Priority dateJan 24, 1990
Fee statusPaid
Also published asUS5468614, US5667973
Publication number07469285, 469285, US 5283173 A, US 5283173A, US-A-5283173, US5283173 A, US5283173A
InventorsStanley Fields, Ok-Kyu Song
Original AssigneeThe Research Foundation Of State University Of New York
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Transcriptional activation
US 5283173 A
Abstract
Methods are provided for detecting the interaction between a first test protein and a second test protein, in vivo, using reconstitution of the activity of a transcriptional activator. This reconstitution makes use of chimeric genes which express hybrid proteins. Two types of hybrid proteins are prepared. The first hybrid contains the DNA-binding domain of a transcriptional activator fused to the first test protein. The second hybrid protein contains a transcriptional activation domain fused to the second test protein. If the two test proteins are able to interact, they bring into close proximity the two domains of the transcriptional activator. This proximity is sufficient to cause transcription, which can be detected by the activity of a marker gene which contains a binding site for the DNA-binding domain.
Images(2)
Previous page
Next page
Claims(9)
We claim:
1. A method for detecting an interaction between a first test protein and a second test protein, the method comprising:
(a) providing a Saccharomyces cerevisiae host cell containing a detectable gene wherein the detectable gene expresses a detectable protein when the detectable gene is activated by an amino acid sequence including a transcriptional activation domain when the transcriptional activation domain is in sufficient proximity to the detectable gene;
(b) providing a first chimeric gene that is capable of being expressed in the host cell, the first chimeric gene comprising a DNA sequence that encodes a first hybrid protein, the first hybrid protein comprising:
(i) a DNA-binding domain that recognizes a binding site on the detectable gene in the host cell; and
(ii) a first test protein or fragment thereof that is to be tested for interaction with at least one second test protein or fragment thereof;
(c) providing a second chimeric gene that is capable of being expressed in the host cell, the second chimeric gene comprising a DNA sequence that encodes a second hybrid protein, the second hybrid protein comprising:
(i) the transcriptional activation domain; and
(ii) a second test protein or fragment thereof that is to be tested for interaction with the first test protein or fragment thereof;
wherein interaction between the first test protein and the second test protein in the host cell causes the transcriptional activation domain to activate transcription of the detectable gene;
(d) introducing the first chimeric gene and the second chimeric gene into the host cell;
(e) subjecting the host cell to conditions under which the first hybrid protein and the second hybrid protein are expressed in sufficient quantity for the detectable gene to be activated; and
(f) determining whether the detectable gene has been expressed to a degree greater than expression in the absence of an interaction between the first test protein and the second test protein.
2. The method according to claim 1, wherein the DNA-binding domain and transcriptional activation domain are derived from transcriptional activators having separable DNA-binding and transcriptional activation domains.
3. The method according to claim 2, wherein the DNA binding domain and the transcriptional activation domain are selected from the group consisting of transcriptional activators GAL4, GCN4 and ADR1.
4. The method according to claim 1, wherein the first hybrid protein or the second hybrid protein is encoded on a library of plasmids containing DNA inserts, derived from the group consisting of genomic DNA, cDNA and synthetically generated DNA.
5. The method according to claim 1, wherein the first test protein is derived from the group consisting of bacterial protein, viral protein, oncogene-encoded protein, growth factor a non-bacterial enzyme and a non-viral enzyme.
6. The method according to claim 1, wherein the chimeric genes are introduced into the host cell in the form of plasmids.
7. The method according to claim 1, wherein the first chimeric gene is integrated into the chromosomes of the host cell.
8. The method according to claim 1, wherein the first chimeric gene is integrated into the chromosomes of the host cell and the second chimeric gene is introduced into the host cell as part of a plasmid.
9. The method according to claim 1, wherein the DNA-binding domain and the transcriptional activation domain are from different transcriptional activators.
Description
BACKGROUND OF THE INVENTION

This invention was partially made with Government support under Grant No. DMB 8601949 awarded by the National Science Foundation. The United States Government has certain rights in this invention.

1. Field of the Invention

The present invention relates to a method for detecting the interaction of proteins in an in vivo system through the use of fused genes encoding hybrid proteins.

2. Background of the Related Art

A fundamental area of inquiry in biology is the analysis of interactions between proteins Proteins are complex macromolecules made up of covalently linked chains of amino acids. Each protein assumes a unique three dimensional shape determined principally by its sequence of amino acids. Many proteins consist of smaller units termed domains, which are continuous stretches of amino acids able to fold independently from the rest of the protein. Some of the important forms of proteins are as enzymes, polypeptide hormones, nutrient transporters, structural components of the cell, hemoglobins, anti-bodies, nucleoproteins, and components of viruses.

Protein-protein interactions enable two or more proteins to associate. A large number of non-covalent bonds form between the proteins when two protein surfaces are precisely matched, and these bonds account for the specificity of recognition. Protein-protein interactions are involved, for example, in the assembly of enzyme subunits; in antigen-antibody reactions; in forming the supramolecular structures of ribosomes, filaments, and viruses; in transport; and in the interaction of receptors on a cell with growth factors and hormones. Products of oncogenes can give rise to neoplastic transformation through protein-protein interactions. For example, some oncogenes encode protein kinases whose enzymatic activity on cellular target proteins leads to the cancerous state. Another example of a protein-protein interaction occurs when a virus infects a cell by recognizing a polypeptide receptor on the surface, and this interaction has been used to design antiviral agents.

Protein-protein interactions have been generally studied in the past using biochemical techniques such as cross-linking, co-immunoprecipitation and co-fractionation by chromatography. A disadvantage of these techniques is that interacting proteins often exist in very low abundance and are, therefore, difficult to detect. Another major disadvantage is that these biochemical techniques involve only the proteins, not the genes encoding them. When an interaction is detected using biochemical methods, the newly identified protein often must be painstakingly isolated and then sequenced to enable the gene encoding it to be obtained. Another disadvantage is that these methods do not immediately provide information about which domains of the interacting proteins are involved in the interaction. Another disadvantage is that small changes in the composition of the interacting proteins cannot be tested easily for their effect on the interaction. A genetic system that is capable of rapidly detecting which proteins interact with a known protein, determining which domains of the proteins interact, and providing the genes for the newly identified interacting proteins has not been available prior to the present invention. Accordingly, to avoid the disadvantages inherent in the biochemical techniques for detecting protein-protein interactions, it would be desirable to have a method for detecting protein-protein interactions using a genetic system. The genetic system described here is based on transcriptional activation. Transcription is the process by which RNA molecules are synthesized using a DNA template. Transcription is regulated by specific sequences in the DNA which indicate when and where RNA synthesis should begin. These sequences correspond to binding sites for proteins, designated transcription factors, which interact with the enzymatic machinery used for the RNA polymerization reaction.

There is evidence that transcription can be activated through the use of two functional domains of a transcription factor: a domain that recognizes and binds to a specific site on the DNA and a domain that is necessary for activation, as reported by Keegan, et al., Science, 231, 699-704 (1986) and Ma and Ptashne, Cell, 48, 847-853 (1987). The transcriptional activation domain is thought to function by contacting other proteins involved in transcription. The DNA-binding domain appears to function to position the transcriptional activation domain on the target gene which is to be transcribed. In a few cases now known, these two functions (DNA-binding and activation) reside on separate proteins. One protein binds to the DNA, and the other protein, which activates transcription, binds to the DNA-bound protein, as reported by McKnight et al, , Proc. Nat'l Acad. Sci. USA, 89, 7061-7065 (1987); another example is reviewed by Curran et al., Cell, 55, 395-397 (1988).

Transcriptional activation has been studied using the GAL4 protein of the yeast Saccharomyces cerevisiae. The GAL4 protein is a transcriptional activator required for the expression of genes encoding enzymes of galactose utilization, see Johnston, Microbiol. Rev., 51, 458-476 (1987). It consists of an N-terminal domain which binds to specific DNA sequences designated UASG, (UAS stands for upstream activation site, G indicates the galactose genes) and a C-terminal domain containing acidic regions, which is necessary to activate transcription, see Keegan et al. (1986), supra., and Ma and Ptashne. (1987), supra. As discussed by Keegan et al., the N-terminal domain binds to DNA in a sequence-specific manner but fails to activate transcription. The C-terminal domain cannot activate transcription because it fails to localize to the UASG, see for example, Brent and Ptashne, Cell, 43, 729-736 (1985). However, Ma and Ptashne have reported (Cell, 51, 113-119 (1987); Cell, 55, 443-446 (1988)) that when both the GAL4 N-terminal domain and C-terminal domain are fused together in the same protein, transcriptional activity is induced. Other proteins also function as transcriptional activators via the same mechanism. For example, the GCN4 protein of Saccharomyces cerevisiae as reported by Hope and Struhl, Cell, 46, 885-894 (1986), the ADR1 protein of Saccharomyces cerevisiae as reported by Thukral et al., Molecular and Cellular Biology, 9, 2360-2369, (1989) and the human estrogen receptor, as discussed by Kumar et al., Cell, 51, 941-951 (1987) both contain separable domains for DNA binding and for maximal transcriptional activation.

None of the aforementioned articles suggests a genetic system to detect protein-protein interactions in vivo using transcriptional activation as an assay.

Accordingly, it is an object of the present invention to provide such a genetic system and related testing kit for detecting protein-protein interactions.

Another object of this invention is to provide a method and kit by which a multiplicity of proteins, such as those encoded by the entire genome of a cell, can be simultaneously tested for interaction with a known protein.

It is a further object of the present invention to provide a method for detection of protein-protein interactions in which the nucleic acid fragments which encode the interacting proteins are immediately available when a positive test occurs.

Yet another object of the present invention is to provide a method for the identification of new genes.

Another object of the present invention is to provide a method which can be used in the design of peptides to be used therapeutically.

A still further object of the invention is to provide a system for testing affinity reagents for protein purification.

SUMMARY OF THE INVENTION

These and other objects are achieved by the present invention which provides a method and a kit for detecting interactions between proteins, in vivo. using reconstitution of the activity of a transcriptional activator. This reconstitution makes use of chimeric genes which express hybrid proteins. Two types of hybrid proteins are prepared. The first hybrid contains the DNA-binding domain of a transcriptional activator fused to the first test protein. The second hybrid protein contains a transcriptional activation domain fused to the second test protein. If the two test proteins are able to interact, they bring into close proximity the two domains of the transcriptional activator. This proximity is sufficient to cause transcription, which can be detected by the activity of a marker gene that contains a binding site for the DNA-binding domain.

One advantage of this method is that a multiplicity of proteins can be simultaneously tested to determine whether any interact with a known protein. For example, a DNA fragment encoding the DNA-binding domain is fused to a DNA fragment encoding the known protein in order to provide one hybrid. This hybrid is introduced into the cells carrying the marker gene. For the second hybrid, a library of plasmids can be constructed which may include, for example, total mammalian complementary DNA (cDNA) fused to the DNA sequence encoding the activation domain This library is introduced into the cells carrying the first hybrid. If any individual plasmid from the library encodes a protein that is capable of interacting with the known protein, a positive signal may be obtained In addition, when an interaction between proteins occurs, the gene for the newly identified protein is readily available.

The system can be of value in the identification of new genes. For example, receptors on the cell surface may be identified for known growth factors, toxins, or surface antigens. Proteins that interact with oncogene-encoded products may be discovered, and these proteins can be of therapeutic value.

The system can be used in the design of peptide inhibitors. For example, peptides that interact with enzymes such as proteases or kinases can be identified and then tested in other systems for their ability to inhibit the enzymatic reaction. Peptides that bind to bacterial or viral proteins can be identified and then tested in other systems for their ability to inhibit these bacteria or viruses.

The system can be used to test affinity reagents for protein purification. Peptides or protein domains can be identified that interact with the known protein of interest and these may then be used in a purification protocol for the known protein.

For a better understanding of the present invention, reference is made to the following description, taken together with the accompanying figures, and the scope of which is pointed out in the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-C schematically represent transcriptional activation by reconstitution of GAL4 activity.

FIGS. 2A-E schematically represent plasmid constructions used in Example 1.

DETAILED DESCRIPTION OF THE INVENTION

A method for detecting the interaction between a first test protein and a second test protein is provided in accordance to the present invention. The method includes providing a host cell, preferably a yeast cell, most preferably Saccharomyces cerevisiae or Schizosaccharomyces pombe. The host cell contains a detectable gene having a binding site for the DNA-binding domain of the transcriptional activator, such that the detectable gene expresses a detectable protein when the detectable gene is transcriptionally activated. Such activation occurs when the transcriptional activation domain of a transcriptional activator is brought into sufficient proximity to the DNA-binding domain of the transcriptional activator.

A first chimeric gene is provided which is capable of being expressed in the host cell. The first chimeric gene may be present in a chromosome of the host cell. The first chimeric gene comprises a DNA sequence that encodes a first hybrid protein. The first hybrid protein contains a DNA-binding domain that recognizes the binding site on the detectable gene in the host cell. The first hybrid protein also contains a first test protein or protein fragment which is to be tested for interaction with a second test protein or protein fragment.

A second chimeric gene is provided which is capable of being expressed in the host cell. In one embodiment, both the first and the second chimeric genes are introduced into the host cell in the form of plasmids. Preferably, however, the first chimeric gene is present in a chromosome of the host cell and the second chimeric gene is introduced into the host cell as part of a plasmid. The second chimeric gene contains a DNA sequence that encodes a second hybrid protein. The second hybrid protein contains a transcriptional activation domain. The second hybrid protein also contains a second test protein or a protein fragment which is to be tested for interaction with the first test protein or protein fragment. Preferably, the DNA-binding domain of the first hybrid protein and the transcriptional activation domain of the second hybrid protein are derived from transcriptional activators having separate DNA-binding and transcriptional activation domains. These separate DNA-binding and transcriptional activation domains are also known to be found in the yeast GAL4 protein, and are also known to be found in the yeast GCN4 and ADR1 proteins. Many other proteins involved in transcription also have separable binding and transcriptional activation domains which make them useful for the present invention. In another embodiment, the DNA-binding domain and the transcriptional activation domain may be from different transcriptional activators. The second hybrid protein may be encoded on a library of plasmids that contain genomic, cDNA or synthetically generated DNA sequences fused to the DNA sequence encoding the transcriptional activation domain.

The interaction between the first test protein and the second test protein in the host cell, therefore, causes the transcriptional activation domain to activate transcription of the detectable gene. The method is carried out by introducing the first chimeric gene and the second chimeric gene into the host cell. The host cell is subjected to conditions under which the first hybrid protein and the second hybrid protein are expressed in sufficient quantity for the detectable gene to be activated. The cells are then tested for their expression of the detectable gene to a greater degree than in the absence of an interaction between the first test protein and the second test protein.

Thus, interactions between a first test protein and a library of proteins can be tested. For example, the first test protein may be derived from a bacterial protein, a viral protein, an oncogene-encoded protein, a growth factor or an enzyme. The second test protein may be derived from a library of plasmids as described above.

The method of the present invention, as described above, may be practiced using a kit for detecting interaction between a first test protein and a second test protein. The kit includes a container, two vectors, and a host cell. The first vector contains a promoter and may include a transcription termination signal functionally associated with the first chimeric gene in order to direct the transcription of the first chimeric gene. The first chimeric gene includes a DNA sequence that encodes a DNA-binding domain and a unique restriction site(s) for inserting a DNA sequence encoding a first test protein or protein fragment in such a manner that the first test protein is expressed as part of a hybrid protein with the DNA-binding domain. The first vector also includes a means for replicating itself in the host cell and in bacteria. Also included on the first vector is a first marker gene, the expression of which in the host cell permits selection of cells containing the first marker gene from cells that do not contain the first marker gene. Preferably, the first vector is a plasmid.

The kit also includes a second vector which contains a second chimeric gene. The second chimeric gene also includes a promorer and a transcription termination signal to direct transcription. The second chimeric gene also includes a DNA sequence that encodes a transcriptional activation domain and a unique restriction site(s) to insert a DNA sequence encoding the second test protein or protein fragment into the vector, in such a manner that the second test protein is capable of being expressed as part of a hybrid protein with the transcriptional activation domain. Preferably, the DNA-binding domain of the first hybrid protein and the transcriptional activation domain of the second hybrid protein are derived from transcriptional activators having separate DNA-binding and transcriptional activation domains. These separate DNA-binding and transcriptional activation domains are also known to be found in the yeast GAL4 protein, and are also known to be found in the yeast GCN4 and ADR1 proteins. Many other proteins involved in transcription also have separable binding and transcriptional activation domains which make them useful for the present invention. In another embodiment, the DNA binding domain and the transcriptional activation domain may be from different transcriptional activators. The second hybrid protein may be encoded on a library of plasmids that contain genomic, cDNA or synthetically generated DNA sequences fused to the DNA sequence encoding the transcriptional activation domain.

The second vector further includes a means for replicating itself in the host cell and in bacteria. The second vector also includes a second marker gene, the expression of which in the host cell permits selection of cells containing the second marker gene from cells that do not contain the second marker gene.

The kit includes a host cell, preferably a yeast strain of Saccharomyces cerevisiae or Schizosaccharomyces pombe. The host cell contains the detectable gene having a binding site for the DNA-binding domain of the first hybrid protein. The binding site is positioned so that the detectable gene expresses a detectable protein when the detectable gene is activated by the transcriptional activation domain encoded by the second vector. Activation of the detectable gene is possible when the transcriptional activation domain is in sufficient proximity to the detectable gene. The host cell, by itself, is incapable of expressing a protein having a function of the first marker gene, the second marker gene, the DNA-binding domain, or the transcriptional activation domain.

Accordingly in using the kit, the interaction of the first test protein and the second test protein in the host cell causes a measurably greater expression of the detectable gene than when the DNA-binding domain and the transcriptional activation domain are present, in the absence of an interaction between the first test protein and the second test protein. The detectable gene may encode an enzyme or other product that can be readily measured. Such measurable activity may include the ability of the cell to grow only when the marker gene is transcribed, or the presence of detectable enzyme activity only when the marker gene is transcribed. Various other markers are well known within the skill of workers in the art.

The cells containing the two hybrid proteins are incubated in an appropriate medium and the culture is monitored for the measurable activity. A positive test for this activity is an indication that the first test protein and the second test protein have interacted. Such interaction brings their respective DNA-binding and transcriptional activation domains into sufficiently close proximity to cause transcription of the marker gene.

In one preferred embodiment, we prepared a system of two hybrid proteins containing domains of a yeast transcriptional activator, the GAL4 protein A yeast strain is used that carries several genes under the regulation of UASG and therefore able to bind the GAL4 DNA-binding domain. One of these genes is GAL1-1acZ, which contains the E. coli 1acZ gene encoding β-galactosidase. Therefore β-galactosidase activity, detected by liquid assay or by colony color on appropriate media, is a measure of GAL4 function Growth of the yeast on galactose requires the transcription of genes regulated by GAL4 and is also a measure of GAL4 function. The host yeast strain carries a deletion of the chromosomal GAL4 gene, such that any GAL4 function must be due to that encoded by the introduced plasmids.

The basic strategy of this testing method is shown in FIG. 1. FIG. 1A schematically illustrates the binding of the native GAL4 protein 10 having a DNA-binding domain 12 and a transcriptional activation domain 14. The native GAL4 protein 10, containing both domains 14, is a potent activator of transcription of the GAL1-1acZ gene 16 when yeast are grown on galactose media. Transcription of the GAL1-1acZ gene 16 is indicated by the arrow 18.

FIG. 1B schematically illustrates two hybrid proteins, 20 and 22. The first hybrid protein 20 contains one of the interacting proteins X and the GAL4 DNA-binding domain 12. The second hybrid protein 22 contains a second interacting protein Y and a portion of the GAL4 activation domain 14A. Neither of these hybrid proteins 20 or 22, alone, is able to activate transcription. The interaction of proteins X and Y, as illustrated in FIG. 1C, allows the portion of the GAL4 activation domain 14A to be brought into sufficient proximity to the DNA-binding domain 12 of GAL4, allowing transcription 18 of GAL1-1acZ gene 16 to occur. Transcriptional activation can be determined by measuring β-galactosidase activity when the yeast are grown on galactose containing media.

The system is dependent on a number of conditions to properly carry out the method of this invention. The first interacting protein X must not, itself, carry an activation domain for the marker. Otherwise the activation domain would allow transcription of the marker gene as soon as the vector encoding only the GAL4 DNA-binding domain fused to the first interacting protein X is introduced. The interaction between the first test protein X and the second test protein Y must be capable of occurring within the yeast nucleus. The GAL4 activation domain portion of the hybrid containing the second test protein Y must be accessible to the transcription machinery of the cell to allow transcription of the marker gene. Should any of these conditions not exist, the system may be modified for use by constructing hybrids that carry only portions of the interacting proteins X and Y and thus meet these conditions.

This system can be used to select genetically for proteins that interact with a known protein, provided the gene encoding the known protein is available. Yeast containing the known protein as a hybrid with the GAL4 DNA-binding domain can be transformed with a clone bank of genomic or cDNA sequences fused to the GAL4 activation domain. The double transformants can be selected for their ability to grow on galactose, or screened for blue color on indicator plates for those transformants able to express the GAL1-1acZ fusion.

Since other eukaryotic cells use a mechanism similar to that of yeast for transcription, other eukaryotic cells such as HeLa cells can be used instead of yeast to test for protein-protein interactions. The reporter gene function can be served by any of a large variety of genes, such as genes encoding drug resistance or metabolic enzymes. The function of GAL4 can be served by any transcriptional activator that has separable domains for DNA-binding and for transcriptional activation. Indeed, any protein, even one that is not a transcriptional activator, that has two separable functions can be used to establish a similar genetic system to detect protein-protein interactions.

Accordingly, the method of the present invention can be applied more generally to any detectable function requiring separable domains of an amino acid sequence which can be reconstituted. This general embodiment of the present invention detects interaction between a first test protein and a second test protein. The method includes providing a host cell which is defective in a detectable function. The detectable function is provided by an amino acid sequence having separable domains. Thus, the amino acid sequence includes a first domain and a second domain which are capable of producing the detectable function when they are in sufficient proximity to each other in the host cell.

A first chimeric gene is provided that is capable of being expressed in the host cell. The first chimeric gene includes a DNA sequence that encodes a first hybrid protein. The first hybrid protein contains the first domain of the amino acid sequence. The first hybrid protein also contains a first test protein or protein fragment which is to be tested for interaction with a second protein or protein fragment.

A second chimeric gene is provided which is capable of being expressed in the host cell. The second chimeric gene contains a DNA sequence that encodes a second hybrid protein. The second hybrid protein contains the second domain of the amino acid sequence. The second hybrid protein also contains a second test protein or protein fragment which is to be tested for interaction with a first test protein or protein fragment.

The interaction between the first test protein and the second test protein in the host cell, causes the function of the amino acid sequence to be reconstituted. The method is thus carried out by introducing the first chimeric gene and the second chimeric gene into the host cell. The host cell is subjected to conditions. under which the first hybrid protein and the second hybrid protein are expressed in sufficient quantity for the function of the amino acid sequence to be reconstituted. The cells are then tested to determine whether their expression of the function of the amino acid sequence has been reconstituted to a degree greater than in the absence of the interaction of the test proteins.

This generalized method can be made more specific, for example, as described suora. for the preferred method of the present invention in which the detectable function is transcription of a detectable gene. In this method, the first domain of the amino acid sequence includes a DNA-binding domain that recognizes a binding site on the detectable gene, and the second of the amino acid sequence includes a transcriptional activation domain.

In the generalized method, described above, the host cell may be any type of cell, including yeast, bacterial, or mammalian cell. The preferred host cell, however, is a bacterial cell. In carrying out this method, the first test protein may be derived from a bacterial protein, a viral protein, an oncogen-encoded protein, a growth factor or an enzyme. The second hybrid protein may be encoded on a library of plasmids containing DNA inserts that are derived from genomic DNA, cDNA, or synthetically generated DNA sequences fused to the DNA sequence encoding the second amino acid domain.

The following example further illustrates the various features of the invention, and is not intended in any way to limit the scope of the invention which is defined by the appended claims.

EXAMPLE

The method and components of the kit for the present invention were tested using GAL4 as the transcriptional activator and two interacting yeast test proteins, SNF1 and SNF4. We have obtained high transcriptional activity only when both hybrid proteins are present in the yeast cell. The SNF1 protein is a serine-threonine specific protein kinase, as reported by Celenza and Carlson in Science, 233, 1175-1180 (1986). The SNF4 protein is physically associated with SNF1 and is required for its maximal activity, see Celenza and Carlson, Molecular and Cellular Biology, 9, 5034-5044 (1989) and Celenza, Eng, and Carlson, Molecular and Cellular Biology, 9, 5045-5054 (1989).

The constructions of the relevant portions of the plasmids used in this example are illustrated in FIG. 2. In FIG. 2, "D" represents the DNA-binding domain of the GAL4 protein; while "A" represents the transcriptional activation domain of the GAL4 protein. FIG. 2A illustrates the entire GAL4 protein of 881 amino acids, designated GAL4 (1-881), based on the gene sequence by Laughon et al., Molecular and Cellular Biology, 4, 260-267 (1984). FIG. 2B illustrates the amino terminal 147 amino acids of GAL4, designated GAL4(1-147), which binds to the GAL upstream activation site (UASG), as described by Keegan et al. (1986), supra. FIG. 2C illustrates the hybrid protein, designated GAL4(1-147)-SNF1, containing the amino terminal domain of GAL4 fused in frame to the entire coding sequence (633 amino acids) of the SNF1 protein. The sequence of the SNF1 protein is described by Celenza and Carlson in Science, 233, 1175-1180 (1986). FIG. 2D illustrates the entire protein designated SNF4, of 322 amino acids, based on the gene sequence by Celenza, Eng, and Carlson (1989) supra. FIG. 2E illustrates a hybrid protein containing all but the last amino acid of SNF4 fused in frame to a GAL4 activation domain designated SNF4-GAL4(768-881). This GAL4 activation domain is sufficient when fused to the GAL4 DNA-binding domain to induce substantial transcriptional activity of the GAL4 gene, see Ma and Ptashne, Cell, 48, 847-853 (1987).

The DNA sequence GAL4(1-881) was carried on plasmid pCL1; GAL4(1-147) was carried on plasmid pMA424; GAL4(1-147)-SNF1 was carried on plasmid pEE5; SNF4 was carried on plasmid pFF1; and SNF4-GAL4(768-881) was carried on plasmid pNI12.

These plasmids were introduced into yeast strain GGY1::171 which is deleted for both GAL4 and GAL80, a negative regulator of GAL4, and which also contains a GAL1-1acZ fusion gene, as described by Gill and Ptashne, in Cell, 51, 121-126 (1987). Thus β-galactosidase activity is a measure of GAL4 function derived from the plasmid-borne GAL4 constructs. The strain also contains mutations of the HIS3 and LEU2 genes, which are the selectable genes on plasmids containing the DNA-binding and activation domains, respectively.

Transformants were grown in media which can induce transcription from UASG. The media contained 2% galactose, 2% ethanol, 2% glycerol, and did not contain either leucine or histidine, or both, as appropriate in order to maintain the plasmids.

The results of this experiment are shown in Table 1.

              TABLE 1______________________________________TRANSCRIPTIONAL ACTIVATIONPRODUCED BY HYBRID GAL4 PROTEINS                   β-galactosidasePlasmid                 activity______________________________________1. None                 <12. GAL4(1-881)          40003. GAL4(1-147)          <14. GAL4(1-147)-SNF1     <15. SNF4                 <16. SNF4-L4(768-881)     <17. GAL4(1-147)-SNF1; SNF4-L4(768-881)                   1808. GAL4(1-147)-SNF1; SNF4                   79. GAL4(1-147); SNF4-GA14(768-881)                   <1______________________________________

As can be seen in Table 1, in the absence of a plasmid containing GAL4 (line 1), β-galactosidase activity was not detected. By contrast, in the presence of the native GAL4 protein (line 2), 4000 units of β-galactosidase activity were detected. The use of the DNA-binding domain GAL4(1-147), alone, did not activate transcription and therefore β-galactosidase activity was not detected (line 3). In addition, the use of a plasmid encoding the GAL4(1-147)-SNF1 hybrid protein did not result in β-galactosidase activity (line 4), indicating that the SNF1 protein domain does not function as a transcriptional activation domain.

In addition, introduction of a plasmid encoding either the intact SNF4 protein (line 5), or the SNF4-GAL4(768-881) hybrid protein (line 6), also failed to activate transcription. When plasmi encoding both GAL4(1-147)-SNF1 and SNF4-GAL4(768-881) were introduced, however, 180 units of β-galactosidase activity were detected (line 7). This level of β-galactosidase activity represented an induction of several hundred-fold over the background level of the single hybrids. Although the activity produced by introduction of the two hybrids is only 4.5% of that produced by the native GAL4 protein expressed from the strong ADH1 promoter, it was sufficient to produce a dark blue colony on plates containing the indicator X-gal. X-gal is an abbreviation for 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside. Accordingly, the yeast cells containing the interacting hybrid proteins which produced blue colonies were easily differentiated from a background of white cells containing only a single hybrid and not expressing β-galactosidase activity.

We have also shown that the induction of transcription and accordingly of β-galactosidase activity produced by the two hybrids is not simply due to the SNF4 protein complexing with the GAL4(1-147)-SNF1 hybrid and converting the GAL4(1-147)-SNF1 hybrid to a transcriptional activator. Thus, introduction of a plasmid encoding the intact SNF4 protein into cells carrying the GAL4(1-147)-SNF1 hybrid was not sufficient for the production of high β-galactosidase activity, although a low level of activity was observed (line 8). In addition, the induction of transcription is not due to the GAL4 activating region interacting with the GAL4 DNA-binding region without the requirement of SNF1-SNF4 interaction (line 9).

The plasmids used in this example were constructed as follows:

pCL1 which contains GAL4(1-881) was constructed by using the BamHI fragment of pLKC15, described by Ma and Ptashne, Cell, 48, 847-853 (1987) and Silver et al., in Proc. Nat'l Acad Sci. USA, 81, 5951-5955 (1984), Which contains the PADH1 -GAL4 gene. This fragment was inserted into a YCp50 derivative in which the LEU2 gene replaces the URA3 gene.

pMA424 containing the GAL4(1-147) genome was constructed as described by Ma and Ptashne, Cell, 51, 113-119 (1987).

pEE5 containing the GAL4(1-147)-SNF1 hybrid is derived from pMA424 and pCC107 of Celenza. pCC107 contains the SNF1 gene in pUC18 and is similar to plasmids described by Celenza and Carlson, Molecular and Cell Biology, 9, 5034-5044 (1989). A PstI site, 12 base-pairs upstream of the codon for the initiator methionine of SNF1, was converted to a BamHI site. Then the BamHI fragment containing the SNF1 gene was inserted into the BamHI site pMA424.

pFF1 containing the SNF4 gene was constructed by inserting the HindIII fragment of pFE27-2, as described by Celenza et al., Molecular and Cell Biology, 9, 5045-5054 (1989), which contains SNF4 gene, into the multi-copy yeast plasmid YEp13, described in Broach et al. Gene, 8, 1221-133 (1979).

pNI12 containing the SNF4-GAL4(768-881) hybrid gene was constructed from a pUC18 clone containing the GAL4 gene and ADH1 terminator (derived from pLKC15) from the NarI site at amino acid 767 of GAL4 to the 3' BamHI site. The NarI site was converted to a KonI site, and the resulting KpnI fragment was ligated to pSL321, described by Celenza et al., Molecular and Cell Biology, 9, 5045-5054 (1989), at a KpnI site, 6 base-pairs downstream of the penultimate amino acid of the SNF4 gene. Then, a HindIII fragment containing the SNF4 promoter and gene fused to the GAL4(768-881) region was inserted into the plasmid YEp13.

While there have been described what are presently believed to be the preferred embodiments of the invention, those skilled in the art will realize that other changes and modifications may be made thereto without departing from the spirit of the invention, and we intend to claim all such changes and modifications as falling within the true scope of the invention.

Non-Patent Citations
Reference
1 *Brent and Ptashne, Cell, 43, 729 736 (1985).
2Brent and Ptashne, Cell, 43, 729-736 (1985).
3 *Broach et al. Gene, 8, 121 123 (1979).
4Broach et al. Gene, 8, 121-123 (1979).
5 *Celenza and Carlson, Molecular and Cellular Biology, 9, 5034 5044 (1989).
6Celenza and Carlson, Molecular and Cellular Biology, 9, 5034-5044 (1989).
7 *Celenza and Carlson, Science, 233, 1175 1180 (1986).
8Celenza and Carlson, Science, 233, 1175-1180 (1986).
9 *Celenza, Eng and Carlson, Molecular and Cellular Biology, 9, 5045 5054 (1989).
10Celenza, Eng and Carlson, Molecular and Cellular Biology, 9, 5045-5054 (1989).
11 *Curran et al., Cell, 55, 395 397 (1988).
12Curran et al., Cell, 55, 395-397 (1988).
13 *Gill and Ptashne, Cell, 51, 121 126 (1987).
14Gill and Ptashne, Cell, 51, 121-126 (1987).
15 *Hope and Struhl, Cell, 46, 885 894 (1986).
16Hope and Struhl, Cell, 46, 885-894 (1986).
17 *Hope et al. Nature 333(96174):635 640, 1988.
18Hope et al. Nature 333(96174):635-640, 1988.
19 *Johnston, Microbiol. Rev., 51, 458 476 (1987).
20Johnston, Microbiol. Rev., 51, 458-476 (1987).
21 *Keegan et al., Science, 231, 699 704 (1986).
22Keegan et al., Science, 231, 699-704 (1986).
23 *Kumar et al., Cell, 51, 941 951 (1987).
24Kumar et al., Cell, 51, 941-951 (1987).
25 *Laughon et al., Molecular and Cellular Biology, 4, 260 267 (1984).
26Laughon et al., Molecular and Cellular Biology, 4, 260-267 (1984).
27 *Ma and Ptashne, Cell, 48, 847 853 (1987).
28Ma and Ptashne, Cell, 48, 847-853 (1987).
29 *Ma and Ptashne, Cell, 51, 113 119 (1987).
30Ma and Ptashne, Cell, 51, 113-119 (1987).
31 *Ma and Ptashne, Cell, 55, 443 446 (1988).
32Ma and Ptashne, Cell, 55, 443-446 (1988).
33 *McKnight et al., Proc. Nat l. Acad. Sci. USA, 84, 7061 7065 (1987).
34McKnight et al., Proc. Nat'l. Acad. Sci. USA, 84, 7061-7065 (1987).
35 *Silver et al., Proc. Nat l Acad. Sci. U.S.A., 81, 5951 5955 (1984).
36Silver et al., Proc. Nat'l Acad. Sci. U.S.A., 81, 5951-5955 (1984).
37 *Thukral et al., Molecular and Cellular Biology, 9, 2360 2369.
38Thukral et al., Molecular and Cellular Biology, 9, 2360-2369.
39 *Wittekind et al., Mol. Cell. Biol. 8(10):3997 4008, Oct. 1988.
40Wittekind et al., Mol. Cell. Biol. 8(10):3997-4008, Oct. 1988.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5468614 *Feb 1, 1994Nov 21, 1995The Research Foundation Of State University Of New YorkSystem to detect protein-protein interactions
US5503977 *Apr 22, 1994Apr 2, 1996California Institute Of TechnologySplit ubiquitin protein sensor
US5580736 *Jan 9, 1995Dec 3, 1996The General Hospital CorporationHaving a cell with a reporter gene linked to a dna sequence comprising a protein binding site, a first and second fusiongene; interacting the binding proteins expressed; measuringthe expression of the reporter gene
US5585245 *Dec 7, 1994Dec 17, 1996California Institute Of TechnologyProtein complex
US5610015 *Mar 23, 1995Mar 11, 1997Wisconsin Alumni Research FoundationSystem to detect protein-RNA interactions
US5637463 *May 4, 1995Jun 10, 1997Hoffmann-La Roche Inc.Method to detect protein-protein interactions
US5656725 *May 12, 1995Aug 12, 1997Apoptosis Technology, Inc.Stabilize inappropriate cell proliferation or cell death
US5667973 *Jun 7, 1995Sep 16, 1997The Research Foundation Of State University Of New YorkChimeric genes expressing hybrid proteins
US5677131 *Jul 9, 1996Oct 14, 1997Wisconsin Alumni Research FoundationSystem to detect protein-RNA interactions
US5691137 *Aug 30, 1994Nov 25, 1997Brandeis UniversityMethods of screening candidate agents for biological activity using yeast cells
US5695941 *Jan 14, 1997Dec 9, 1997The General Hospital CorporationUsing saccharomyces cell which contains reporter gene linked to protein binding site and fusion gene; for detecting protein-protein interactions
US5700638 *May 25, 1994Dec 23, 1997Washington UniversityCell death regulator
US5733726 *Jun 7, 1995Mar 31, 1998Emory UniversityCytotoxicity-based genetic selection system (TOXSEL)
US5750667 *Nov 12, 1996May 12, 1998Wisconsin Alumni Research FoundationSystem to detect protein-RNA interactions
US5753446 *Jun 6, 1995May 19, 1998National Jewish Center For Immunology & Respiratory MedicineMitogen ERK kinase kinase (MEKK) assay
US5773225 *May 24, 1994Jun 30, 1998The Trustees Of Columbia University In The City Of New YorkIncubating cyclophilin affinity fusion protein; complexing; binding to affinity medium; comparing to control
US5776689 *Jul 19, 1996Jul 7, 1998The Regents Of The University Of CaliforniaProtein recruitment system
US5776716 *Jan 31, 1996Jul 7, 1998Terrapin Technologies, Inc.Mixing protein kinase c with tyrosine protein kinase and subject compound; determining whether binding is reduced
US5783405 *Oct 10, 1995Jul 21, 1998Terrapin Technologies, Inc.Rapid screening method for effectors of signal transduction
US5786169 *Jun 5, 1995Jul 28, 1998The General Hospital CorporationCDI1 polypeptides
US5789184 *Jun 5, 1995Aug 4, 1998Cadus Pharmaceutical CorporationYeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5795735 *Jul 17, 1995Aug 18, 1998Icos CorporationIsolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly
US5798245 *Oct 6, 1994Aug 25, 1998Dana-Farber Cancer InstituteTIA-1 binding proteins and isolated complementary DNA encoding the same
US5830707 *Jun 5, 1995Nov 3, 1998The Salk Institute For Biological StudiesGenetic engineered retroviruses
US5846711 *Apr 4, 1994Dec 8, 1998The General Hospital CorporationNuclear hormone receptor-interacting polypeptides and related molecules and methods
US5846722 *Oct 16, 1996Dec 8, 1998Terrapin Technologies, Inc.System to detect small molecule/peptide interaction
US5863795 *Aug 8, 1997Jan 26, 1999Apoptosis Technology, Inc.Nucleic acids that encode peptides which modulate apoptosis
US5866686 *Jun 6, 1995Feb 2, 1999The General Hospital CorporationNuclear thyroid hormone receptor-interacting polypeptides and related molecules and methods
US5871945 *Jul 17, 1995Feb 16, 1999Icos CorporationModulators of anchoring protein function
US5874534 *Jun 6, 1995Feb 23, 1999Baylor College Of MedicineMutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5876951 *Jun 5, 1995Mar 2, 1999Cadus Pharmaceutical CorporationYeast cells engineered to produce pheromone system protein surrogates and uses therefor
US5885779 *Sep 9, 1997Mar 23, 1999University Of British ColumbiaRepressed trans-activator system for characterization of protein-protein interactions
US5885797 *Aug 27, 1996Mar 23, 1999Fred Hutchinson Cancer Research CenterPolynucleotide sequences encoding proteins involved in myogenesis
US5925523 *Aug 26, 1997Jul 20, 1999President & Fellows Of Harvard CollegeIntraction trap assay, reagents and uses thereof
US5928868 *Apr 25, 1997Jul 27, 1999Massachusetts Institute Of TechnologyThree hybrid screening assay
US5935803 *Jun 18, 1996Aug 10, 1999Terrapin Technologies, Inc.Methods to identify immunomodulators using cognate interaction of PKC-theta
US5935934 *May 30, 1995Aug 10, 1999Baylor College Of MedicineMutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5948620 *Aug 4, 1997Sep 7, 1999Amersham International PlcReverse two-hybrid system employing post-translation signal modulation
US5948656 *Feb 4, 1997Sep 7, 1999Dana-Farber Cancer InstituteProteins which bind to cytolytic lymphocyte cytoplasmic granule associated rna binding proteins; anticarcinogenic agents; treatment of graft vs. host disease, allograft rejection, transplantation organ rejections
US5955275 *Mar 4, 1997Sep 21, 1999Arcaris, Inc.Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US5955280 *Sep 4, 1997Sep 21, 1999The General Hospital CorporationDetermining sensitivity of two distinct proteins to each other in cells that are mating by detecting expression of reporter genes
US5962256 *Jun 6, 1995Oct 5, 1999The General Hospital CorporationNuclear thyroid hormone receptor-interacting polynucleotides and related molecules and methods
US5962312 *Nov 25, 1996Oct 5, 1999Sugen, Inc.Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US5965368 *Oct 24, 1997Oct 12, 1999The General Hospital CorporationDetermining protein-protein interactions by counterselection of two test proteins expressed in two separate nucleic acid libraries and measuring level of expression of reporter gene operably linked to a dna-binding-protein recognition sites
US5968738 *Dec 6, 1996Oct 19, 1999The Board Of Trustees Of The Leland Stanford Junior UniversityTwo-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5972676 *Nov 19, 1997Oct 26, 1999Sugen, Inc.Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US5981265 *Jun 5, 1995Nov 9, 1999National Jewish Center For Immunology And Respiratory MedicineControlling mitogen kinase polypeptide activity in a cell using transformation and transfection; for treating animals having cancer, inflammation, neurological disorders, autoimmune diseases, allergiies; anticarcinogenic agents
US5989808 *Jun 14, 1994Nov 23, 1999American Cyanamid CompanyIdentification of compounds affecting specific interaction of peptide binding pairs
US5994304 *Aug 17, 1998Nov 30, 1999Icos CorporationPolypeptide
US6004746 *Jul 20, 1995Dec 21, 1999The General Hospital CorporationInteraction trap systems for detecting protein interactions
US6048693 *Oct 16, 1997Apr 11, 2000Bittech, Inc.Screening for modulators of mammalian cell cycle regulatory proteins; administering a compound to a cell line and analyzing the expression of a reporter gene in the cell line, thereby determining whether the compound affects normal
US6054286 *Jan 15, 1999Apr 25, 2000Telik, Inc.Detecting modulators of immune response; incubation of protein kinase c with modulator and ascertaining presence of modulating activity
US6057101 *Jun 13, 1997May 2, 2000Curagen CorporationIdentification and comparison of protein-protein interactions that occur in populations and identification of inhibitors of these interactors
US6083693 *Jun 14, 1996Jul 4, 2000Curagen CorporationIdentification and comparison of protein-protein interactions that occur in populations
US6087177 *Apr 29, 1994Jul 11, 2000Wohlstadter; Jacob NathanielSelection methods
US6100042 *Oct 13, 1994Aug 8, 2000Cadus Pharmaceutical CorporationYeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6114111 *Mar 30, 1998Sep 5, 2000Rigel Pharmaceuticals, Inc.Mammalian protein interaction cloning system
US6132963 *Oct 14, 1997Oct 17, 2000The General Hosptial CorporationNucleotide sequences coding modulator protein; for the detection of modulation of signal transduction
US6159705 *Sep 24, 1997Dec 12, 2000Cadus Pharmaceutical CorporationScreening by using yeast cell which expresses a heterologous receptor which is functionally integrated into an endogenous yeast signaling pathway, contacting with a test compound, and detecting alteration in signal
US6165733 *May 22, 1997Dec 26, 2000Chiron CorporationDrug screening for inhibitors of mitogenesis; using cell having two fusion proteins which regenerate a transcriptional activating factor, contacting cell with compound, and measuring expression of reporter gene
US6171792Nov 10, 1998Jan 9, 2001The General Hospital CorporationDetection systems for registering protein interactions and functional relationships
US6184202Sep 11, 1997Feb 6, 2001Washington UniversityModulating apoptosis of a cell by administering an agent comprising a bh1 or bh2 domain capable of promoting or inhibiting formation of a complex of bcl-2:blc-2; bcl-xl:bcl-xl; bax:bax; and/or bcl-xl:bax
US6187535Feb 18, 1998Feb 13, 2001Institut PasteurIsolating preferential nucleotide sequences coding binding proteins; providing yeast cell mix, mate and plate yeast, isolate diploid yeast, classify nucleotide sequences in diploid yeast cell
US6191257 *Jun 7, 1995Feb 20, 2001Baylor College Of MedicineNatural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy
US6197599 *Jul 30, 1998Mar 6, 2001Guorong ChinMethod to detect proteins
US6200746Aug 25, 1999Mar 13, 2001Pharmacia & Upjohn CompanyDetection of enzyme inhibitor; evaluate kinase phosphorylation in presence and absence of virus, incubate with test compound, monitor decrease in enzyme activity
US6200759Apr 21, 1999Mar 13, 2001President And Fellows Of Harvard CollegeInteraction trap assay, reagents and uses thereof
US6207401Mar 31, 1999Mar 27, 2001Sugen, Inc.Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US6221615Jan 25, 1999Apr 24, 2001Apoptosis Technology, Inc.Detection of modulators cell killing; mixing modulators of heterodimerization and detecting reduction in heterodimer forming activity
US6222024May 24, 1994Apr 24, 2001The Trustees Of Columbia University In The City Of New YorkNucleic acids encoding a human immunodeficiency virus type 1 (HIV-1) integrase interactor protein (INI-1)
US6228641May 19, 1998May 8, 2001Sugen, Inc.Diagnosis and treatment of PTP04 related disorders
US6228647Jan 15, 1999May 8, 2001Iowa State University Research Foundation, Inc.Transposable element protein that directs DNA integration to specific chromosomal sites
US6242183Feb 12, 1999Jun 5, 2001The General Hospital CorporationInteraction trap systems for detecting protein interactions
US6251602Mar 8, 1999Jun 26, 2001American Cyanamid CompanyCell systems having specific interaction of peptide binding pairs
US6251605Oct 25, 1999Jun 26, 2001Cadus Pharmaceutical CorporationYeast cells having mutations in Cav1 and uses therefor
US6255059Jan 17, 1996Jul 3, 2001Cadus Pharmaceutical CorporationMethods for identifying G protein coupled receptor effectors
US6261772Jan 29, 1999Jul 17, 2001Duke UniversityPreparing reporter construct and an effector construct, transforming into vertebrate cells in the presence/absence of test compound; measuring expression of indicator gene, indicating compounds ability to modulate rna-protein binding
US6262023Jun 7, 1995Jul 17, 2001The Board Of Trustees Of The Leland Stanford Junior UniversityWD-40 derived peptides and uses thereof
US6262340Jul 10, 1998Jul 17, 2001Kosan Biosciences, Inc.Production of polyketides in plants
US6284519May 6, 1999Sep 4, 2001American Cyanamid CompanyNucleotide sequences encoding heterologous fusion proteins which interact extracellularly to produce a transcriptional activation protein which activates a reporter gene; production of selected phenotype
US6303310 *Jul 21, 1999Oct 16, 2001Guilford Pharmaceuticals Inc.Screening library for peptides or proteins with preferential functions; provide cells and plasmid, transform cells, detect and monitor protein interactions
US6303319Feb 21, 1997Oct 16, 2001Ariad Pharmaceuticals, Inc.Cell based assay for identifying sh2-domain-specific signal transducer antagonist
US6316223Jul 22, 1999Nov 13, 2001Rigel Pharmaceuticals, Inc.Mammalian protein interaction cloning system
US6326166Dec 29, 1995Dec 4, 2001Massachusetts Institute Of TechnologyNucleotide sequences coding polypeptides; for use as tools in genetic engineering; for use in expression of heterologous polypeptides
US6332897 *Mar 27, 1998Dec 25, 2001Glaxo Wellcome Inc.Assay methods
US6342368Jun 7, 1995Jan 29, 2002The Board Of Trustees Of The Leland Stanford Junior UniversityWD-40-derived peptides and uses thereof
US6342593Jun 10, 1998Jan 29, 2002Sugen, Inc.Diagnosis and treatment of ALP related disorders
US6344549Oct 14, 1999Feb 5, 2002Icos CorporationA polypeptide related to the phosphatidylinositol kinase family; for understanding cell mitosis
US6355473May 5, 1999Mar 12, 2002Cadus Pharmaceutical Corp.Yeast cells having mutations in stp22 and uses therefor
US6365344Jan 23, 1996Apr 2, 2002The Board Of Trustees Of The Leland Stanford Junior UniversityScreening library of randomized nucleic acids using retroviral vectors to transfect mammalian cells, expressing as extracellular bioactive peptides, contacting other mammalian cells, and screening for changed physiology
US6365361Feb 28, 2000Apr 2, 2002Tanabe Seiyaku Co., Ltd.Method for identifying or screening agonist and antagonist to PPAR
US6388063Jun 17, 1998May 14, 2002Sugen, Inc.Diagnosis and treatment of SAD related disorders
US6395478Jan 12, 1999May 28, 2002Curagen CorporationIdentification and comparison of protein-protein interactions that occur in populations and indentification of inhibitors of these interactors
US6399296Apr 9, 1996Jun 4, 2002The General Hospital CorporationDetecting specific protein in sample by contacting with second protein having reduced structural flexibility due to recombinantly introduced disulfide bonding, allowing proteins to complex, then detecting complex
US6410239Dec 14, 1999Jun 25, 2002Curagen CorporationIdentification and comparison of protein—protein interactions that occur in populations and identification of inhibitors of these interactors
US6410246Jun 23, 2000Jun 25, 2002Genetastix CorporationHighly diverse library of yeast expression vectors
US6410254May 18, 1999Jun 25, 2002CytokineticsCompositions and assays utilizing ADP or phosphate for detecting protein modulators
US6410271Jun 23, 2000Jun 25, 2002Genetastix CorporationGpreparing preferential yeast expression vectors; obtain yeast vector, transform yeast with nucleotide sequences, insert preferential nucleotide sequences into vector, recover vector
US6410312Dec 10, 1998Jun 25, 2002Chiron CorporationhuBUB3 gene involved in human cancers
US6413744 *Aug 25, 2000Jul 2, 2002Immunex CorporationMethods and host cells for improved cell culture
US6416998Jun 7, 1995Jul 9, 2002Baylor College Of MedicinePolypeptides
US6423684Jun 7, 1995Jul 23, 2002The Board Of Trustees Of The Leland Stanford Junior UniversityWD-40 derived peptides and uses thereof
US6455247Jan 23, 1997Sep 24, 2002Board Of Trustees Of The Leland Stanford Junior UniversityIntroducing library of randomized nucleic acids linked to secretion signal into cells, expressing nucleic acids to form peptides, and screening second cells which are co-cultured with first cells for altered phenotypes
US6455323Jul 3, 1997Sep 24, 2002Pharmacia & Upjohn CompanyContacting virulence protein with chemical compound, then identifying compounds which bind or interacts with protein; for bactericides against staphylococcus aureus
US6482605Oct 29, 1999Nov 19, 2002Sugen, Inc.Protein tyrosine phosphatase PTP20 and related products and methods
US6485899Mar 16, 2000Nov 26, 2002Pharmacia & Upjohn CompanyAnti-bacterial methods and materials
US6489137Jun 11, 1998Dec 3, 2002Chiron CorporationFor use in cancer diagnostics; detection of the loss and or alteration of wild-type hubub1 genes in tumor tissues
US6489441Sep 1, 1995Dec 3, 2002The Salk Institute For Biological StudiesTranscriptional co-repressor that interacts with nuclear hormone receptors
US6495353Jan 20, 1999Dec 17, 2002Sugen, Inc.Identification of protein kinase proteins which are human orthologues of the drosophila wart gene (hwart); tumor suppressor genes
US6504008Feb 1, 1999Jan 7, 2003Cadus Technologies, Inc.Cell based signal generation
US6509152 *Jan 23, 1998Jan 21, 2003Ariad Gene Therapeutics, Inc.Immunosuppressant target proteins
US6531284Aug 14, 2000Mar 11, 2003Institut PasteurSubjecting polynucleotide to a two-hybrid screening method (mating); selecting the recombinant diploid yeast cell for which the detectable gene has been expressed
US6541615Nov 14, 1997Apr 1, 2003Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V.SIRP proteins and uses thereof
US6555325Jun 12, 2000Apr 29, 2003Cadus Technologies, Inc.Kit for screening of test compounds that modulate a heterologous G protein-coupled receptor in a yeast cell uses a mixture of yeast cells; modulators of heterologous receptors coupled to the pheromone response pathway in yeast
US6562576 *Jan 4, 2002May 13, 2003Myriad Genetics, Inc.Detecting preferential protein activity; obtain yeast cell, generate preferential protein in cell, detect reporter molecules
US6566057Nov 6, 1998May 20, 2003Deltagen Proteomics, Inc.Methods and compositions for peptide libraries displayed on light-emitting scaffolds
US6573364Mar 10, 1999Jun 3, 2003Curagen CorporationIsolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteins
US6579675May 26, 1999Jun 17, 2003Deltagen Proteomics, Inc.Methods for identifying nucleic acid sequences encoding agents that effect cellular phenotypes
US6599698Dec 9, 1998Jul 29, 2003Baylor College Of MedicineMutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6607880 *Mar 2, 1998Aug 19, 2003Mcgill UniversityMethods and reagents for modulating apoptosis
US6623922Feb 14, 1997Sep 23, 2003Deltagen ProteomicsMethods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements
US6627747Sep 9, 1999Sep 30, 2003Millenium Pharmaceuticals, Inc.Essential bacterial genes and their use
US6641994Dec 1, 2000Nov 4, 2003Pharmacia & Upjohn CompanyMethods of identifying anti-viral agents
US6645501Feb 1, 2001Nov 11, 2003Washington UniversityAnti-pathogen system and methods of use thereof
US6656696Feb 26, 1999Dec 2, 2003CyclacelCompositions and methods for monitoring the phosphorylation of natural binding partners
US6670144 *Feb 23, 2000Dec 30, 2003Cyclacel, Ltd.As a function of the addition or subtraction of a phosphate group to or from one of the binding partners by a protein kinase or phosphatase.
US6673540Nov 17, 2000Jan 6, 2004American Cyanamid CompanyCell systems having specific interaction of peptide binding pairs
US6677144Jul 10, 2001Jan 13, 2004Applera CorporationIsolated nucleic acid molecules encoding human pyruvate dehydrogenase E1-alpha subunit proteins
US6716575Jan 22, 1998Apr 6, 2004Sugen, Inc.Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716614Jul 23, 2002Apr 6, 2004Lexicon Genetics IncorporatedPolynucleotides encoding proteins that share sequence similarity with human calcium dependent proteases, specifically calpains.
US6723840Nov 28, 2000Apr 20, 2004The Regents Of The University Of CaliforniaNucleic acid sequence encoding a thermomyces lanuginosus-gamma , (tl- gamma ) protein comprising a specific amino acid sequence
US6737241Jul 27, 2001May 18, 2004Rigel Pharmaceuticals, Inc.Methods for screening for transdominant intracellular effector peptides and RNA molecules
US6740485Jul 3, 1998May 25, 2004Imperial College Innovations LimitedIdentification of genes responsible for the virulence of staphylococcus bacteria, which allows for identification of new anti-bacterial agents and mutants that can be used as vaccines
US6743599Mar 25, 2002Jun 1, 2004Cytokinetics, Inc.For drug screening; can be used in a high throughput system
US6749858Jul 5, 2002Jun 15, 2004Millennium Pharmaceuticals, Inc.Nucleotide sequences coding polypeptide for use in the prevention of streptoccocus infection
US6764830Jan 22, 1999Jul 20, 2004The Regents Of The University Of CaliforniaFor diagnosis, treatment of nervous system disorders, infections, crop protection, veterinary applications, and identifying binding agents and modulators
US6770446 *Apr 24, 2000Aug 3, 2004WyethCell systems having specific interaction of peptide binding pairs
US6797501Sep 16, 2002Sep 28, 2004Max-Planck-Gessellschaft Zur Fonderung De Wissenschaften E.V.Protein tyrosine phosphatase PTP20 and related products and methods
US6797513Jul 17, 2001Sep 28, 2004Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Nucleic acid encoding CLK2 protein kinases
US6800733Dec 17, 2001Oct 5, 2004The Regents Of The University Of CaliforniaGenetically adjusted fluorescent protein for use as detection tool genetic engineering
US6815169Nov 28, 2000Nov 9, 2004The Regents Of The University Of CaliforniaIdentification and expression of a novel kinesin motor protein
US6815532Sep 21, 2001Nov 9, 2004Icos CorporationFor use in cancer therapy
US6818440Apr 27, 1998Nov 16, 2004Sugen, Inc.Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders and alzheimer's
US6828421May 14, 2002Dec 7, 2004Myriad Genetics, Inc.VAMP-associated protein A-interacting proteins and use thereof
US6831154May 14, 2002Dec 14, 2004Myriad Genetics, Inc.For drug screening/diagnosis/therapy/prevention; fusion proteins
US6833245Mar 12, 2002Dec 21, 2004Rigel Pharmaceuticals, Inc.Methods for screening for transdominant effector peptides and RNA molecules
US6841352Jun 28, 2002Jan 11, 2005Myriad Genetics, Inc.Mating-based method for detecting protein—protein interaction
US6844177Apr 2, 2001Jan 18, 2005Sugen, Inc.Diagnosis and treatment of PTP04 related disorders
US6858382Jan 9, 2001Feb 22, 2005The General Hospital CorporationDetection systems for registering protein interactions and functional relationships
US6858419Nov 13, 2001Feb 22, 2005Lexicon Genetics IncorporatedComprises phosphorylating protein for diagnosis, prognosis, drug screening, clinical monitoring and treatment of hypertension
US6858429Aug 23, 2002Feb 22, 2005The Regents Of The University Of CaliforniaUniversal light-switchable gene promoter system
US6864060Oct 7, 1997Mar 8, 2005Cadus Technologies, Inc.Yeast cells expressing modified G proteins and methods of use therefor
US6867189Jul 22, 2002Mar 15, 2005Genset S.A.Such as obesity, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension
US6878523May 8, 2002Apr 12, 2005Gentel Bio Surfaces, Inc.Molecular interaction assays on a solid surface
US6902886Nov 5, 1999Jun 7, 2005The Research Foundation Of State University Of New YorkChimeric nucleic acids; recombinant host cells; fusion protein comprises a DNA binding domain for reporter gene, activation domain, and the protein of interest; modified LexA protein has no nuclear localization signal; mLexA-Gal4AD hybrid fused with
US6905818 *May 30, 2000Jun 14, 2005Max-Planck-Gesellschaft Zur Forderungder WissenschaftenDetection cloning; isolation hybrids; using labels; genetic engineering
US6913886Oct 25, 2002Jul 5, 2005Institut PasteurFast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
US6958214Apr 12, 2001Oct 25, 2005Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US7008780May 10, 2001Mar 7, 2006Massachusetts Institute Of TechnologyChimeric DNA-binding proteins
US7022513Jul 18, 2002Apr 4, 2006Cadus Technologies, Inc.Signal transduction; screening bactericides, viricides, fungicides, parasiticides
US7033768Dec 21, 2001Apr 25, 2006The General Hospital CorporationReverse two-hybrid systems
US7045298Apr 1, 2002May 16, 2006Tanabe Seiyaku Co., Ltd.Method for identifying or screening agonist and antagonist to PPAR
US7049076Jul 9, 2004May 23, 2006Sentigen Biosciences, Inc.Method for assaying protein—protein interaction
US7060506Jan 25, 2001Jun 13, 2006Cyclacel, Ltd.Monitoring preferential enzymatic activity; obtain polypeptide sample, incubate with binding partners, detect bound polypeptide
US7067312Sep 19, 2002Jun 27, 2006Myriad Genetics, Inc.PN7718 nucleic acids and use thereof
US7074589Jun 17, 1997Jul 11, 2006Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Nucleic acid molecules encoding full length PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptides, portions of such nucleic acid molecules, nucleic acid vectors containing such nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such cells
US7090991Mar 31, 2003Aug 15, 2006Cadus Technologies, Inc.System for detection of a functional interaction between a compound and a cellular signal transduction component
US7091038Sep 26, 2001Aug 15, 2006Rheogene, Inc.Ecdysone receptor-based inducible gene expression system
US7091173Oct 30, 2002Aug 15, 2006Myriad Genetics, Inc.FAP48-interacting proteins and use thereof
US7097982Apr 10, 2001Aug 29, 2006Immunogen, Inc.Peptides and compositions which modulate apoptosis
US7105309Oct 1, 2002Sep 12, 2006Cadus Technologies, Inc.Yeast cells engineered to produce pheromone system protein surrogates and uses therefor
US7109297Sep 13, 2004Sep 19, 2006The Hong Kong Polytechnic UniversityBiomarkers for toxic algae
US7115640Nov 18, 2003Oct 3, 2006X-Ceptor Therapeutics, Inc.modulating farnesoid X receptor (FXR), liver X receptors (LXR alpha and LXR beta ) and/or orphan nuclear receptors; treatment of lipid, cardiovascular and neurodegenerative disorders
US7115710Jun 10, 1998Oct 3, 2006Sugen, Inc.PTP05 or PTP10 polypeptide; nucleic acid encoding the peptide and probe for detecting the nucleic acid; recombinant cell; treating diseases caused by PTP abnormality like cancer and diabetes
US7118873Dec 12, 2001Oct 10, 2006The University Of ConnecticutPolynucleotides encoding cellular transporters and methods of use thereof
US7119174Dec 15, 2003Oct 10, 2006Sugen, Inc.AURORA-1/2 (AUR1/2) antibodies or fragments thereof; humanized monoclonal antibodies; hybridomas; immunoassay; for treatment of cancer and screening cell growth inhibitors
US7122305Dec 21, 2000Oct 17, 2006Cadus Technologies, Inc.Methods and compositions for identifying receptor effectors
US7129326Nov 25, 2002Oct 31, 2006Genencor International, Inc.Methods for selective targeting
US7166445Feb 28, 2005Jan 23, 2007Immunex CorporationEukaryotic host cell genetically engineered to express a gene for a protein as an extracellular product, and to express IGF(insulin-like growth factor)-1-signaling pathway gene; cell lines in serum-free and/or protein-free and/or peptone-free media
US7202051Nov 8, 2005Apr 10, 2007Cytokinetics, Inc.Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7223533Dec 1, 2003May 29, 2007Cadus Technologies, Inc.Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
US7229766Jun 20, 2003Jun 12, 2007The Penn State Research FoundationUsing cytoplasmic nuclear export sequences (NES) and/or nuclear localization sequence (NLS) to detect and monitor protein-protein interactions
US7230089May 15, 2000Jun 12, 2007Fred Hutchinson Cancer Research CenterNucleotide sequence that encodes BRO4 encode proteins capable of binding to and inactivating the activity of plant D-like cyclin/cyclin dependent kinase complexes preventing plant cells from exiting the cell cycle
US7235648Feb 26, 1999Jun 26, 2007Cadus Technologies, Inc.Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US7238474Oct 6, 2000Jul 3, 2007Florida State University Research FoundationMaterials and methods for detecting interaction of CFTR polypeptides
US7250263Jan 5, 2004Jul 31, 2007Cadus Technologies, Inc.Methods and compositions for identifying receptor effectors
US7258999Nov 10, 2003Aug 21, 2007Wyethparathyroid hormone (PTH) for drug screening, diagnosis and development of therapies for bone related disorders; genetic engineering
US7261881May 20, 1999Aug 28, 2007Yale UniversityProviding an agent capable of inducing a leptin or leptin receptor-mediated angiogenic response; and administering to a subject in need of wound healing, an effective amount of the agent to promote wound healing, wherein the agent is leptin
US7273747Oct 8, 2002Sep 25, 2007Cadus Technologies, Inc.Cell having amplified signal transduction pathway responses and uses therefor
US7297515Oct 28, 2002Nov 20, 2007Myriad Genetics, Inc.Modulation of the novel zinc finger proteins and their interactions with ZNF202 can be useful in the treatment of coronary heart diseases, dyslipidemia, dyscholesterolemia and obesity
US7297524Jan 12, 2006Nov 20, 2007Thallion Pharmceuticals Inc.Polynucleotides for production of farnesyl dibenzodiazepinones
US7304161Feb 9, 2004Dec 4, 2007Intrexon CorporationDiaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162Feb 19, 2004Dec 4, 2007Intrexon CorporationRegulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide
US7309783May 9, 2002Dec 18, 2007The University Of ConnecticutMammalian early developmental regulator gene
US7319009Oct 22, 2002Jan 15, 2008Cadus Technologies, Inc.Genetically engineered cell coding G protein coupled formyl peptide orphan receptor (FPRL-1) for monitoring adjustment in chemotaxis and cell respiratory activity; drug screening
US7358088Aug 10, 2006Apr 15, 2008Immunogen, Inc.And GD domains by determining if agent inhibits or augments heterodimerization of polypeptides; use in diagnosis of degenerative disorders (inflammatory conditions, cancer)
US7361498Oct 15, 2004Apr 22, 2008Cadus Technologies, Inc.Transgenic yeast comprising g-protein coupled orphan receptors for use as tools in identifying ion channel modulators
US7374932Dec 29, 2004May 20, 2008Lexicon Pharmaceuticals, Inc.Human kinases and polynucleotides encoding the same, and uses thereof
US7378254Jan 18, 2007May 27, 2008CytokineticsCytoskeletal filament proteins, tubulin and actin; ATPases; drug screening; motor proteins; high throughput assay
US7416849May 13, 2002Aug 26, 2008Oscient Pharmaceuticals CorporationHBM variants that modulate bone mass and lipid levels
US7416856Dec 6, 2005Aug 26, 2008Cytokinetics, Inc.High sensitivity assay for detection of nucleoside diphosphate production
US7416881Apr 5, 1999Aug 26, 2008Cadus Technologies, Inc.Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US7425412Jul 26, 2006Sep 16, 2008The Hong Kong Polytechnic UniversityDetermining whether a naturally occurring strain of algae is toxic, comprisingdetermining whether a sample obtained from said strain of algae comprises a nucleic acid encoding a specific polypeptide; harmful algal blooms; shellfish; gene expression
US7429466Jun 18, 2002Sep 30, 2008Hypromatrix, IncMethods and arrays for detecting biological molecules
US7432342May 1, 2003Oct 7, 2008Sequenom, Inc.Kinase anchor protein muteins, peptides thereof and related documents
US7456315Feb 26, 2004Nov 25, 2008Intrexon CorporationBioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7459434Aug 4, 2004Dec 2, 2008Les Laboratories ServierPeptide interacting with anti-apoptotic proteins of the Bcl-2 family
US7468350Dec 8, 2004Dec 23, 2008Pneumrx, Inc.Glue composition for lung volume reduction
US7485441Mar 7, 2006Feb 3, 2009Massachusetts Institute Of TechnologyChimeric DNA-binding proteins
US7504230 *Nov 13, 2003Mar 17, 2009Trelolis Bioscience, Inc.for drug screening by assessing the effect on localization of signal transduction proteins, particularly the protein kinase C (PKC) isoenzymes
US7531326Feb 20, 2002May 12, 2009Intrexon CorporationChimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
US7553810Dec 8, 2004Jun 30, 2009Pneumrx, Inc.Methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume, glue featuring an adhering moiety coupled to one or more other moieties including a cross-linkable moiety and/or one other adhering moiety; use in treating pulmonary conditions, emphysema, copd
US7563879Feb 20, 2002Jul 21, 2009Intrexon Corporationreceptor-based gene expression modulation system for drug screening; genetic engineering
US7563928Aug 20, 2007Jul 21, 2009Intrexon CorporationBioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7572575Apr 13, 2006Aug 11, 2009Massachusetts Institute Of TechnologyIdentifying modulator of transcriptional activity of silent information regulator (SIR) for treat cell proliferative diseases; antitumor agents
US7595375Jun 6, 2002Sep 29, 2009RikenGenetically engineered protein for use as diagnostic tool in gentic analysis
US7601508Aug 17, 2007Oct 13, 2009Intrexon CorporationEcdysone receptor polypeptide from the homopteran whitefly (Bamecia argentifoli, BaEcR) use screening for monoclonal antibodies; biological insecticides
US7601533Feb 13, 2006Oct 13, 2009The General Hospital CorporationReverse two-hybrid systems
US7608579Dec 8, 2004Oct 27, 2009Pneumrx, Inc.Lung volume reduction using glue compositions
US7611854Jun 18, 2003Nov 3, 2009Cadus Technologies, Inc.improve the signal-to-noise ratio of the screening/selection system; for drug screening enzyme inhibitors; genetic engineering
US7625700 *May 23, 2005Dec 1, 2009Odyssey Thera, Inc.In vivo library-versus-library selection of optimized protein-protein interactions
US7635572Jun 9, 2004Dec 22, 2009Life Technologies CorporationMethods for conducting assays for enzyme activity on protein microarrays
US7668658Oct 15, 2002Feb 23, 2010Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US7678767Dec 8, 2004Mar 16, 2010Pneumrx, Inc.Glue compositions for lung volume reduction
US7686995Aug 15, 2008Mar 30, 2010Z CorporationThree-dimensional printer
US7732663Jul 11, 2006Jun 8, 2010Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-FoodUsing transgene expression of enzyme inhibitors and associated factors to control morphological characteristics such as size and shape of crop plants
US7763446Dec 10, 2008Jul 27, 2010Massachusetts Institute Of Technologynucleic acids encoding a chimeric protein comprising a cleavage domain and a composite nucleic acid-binding region, that comprises at least two component polypeptide portions which are individually capable of binding specific nucleotide sequences
US7766938Jul 8, 2005Aug 3, 2010Pneumrx, Inc.Pleural effusion treatment device, method and material
US7776587Aug 20, 2007Aug 17, 2010Intrexon CorporationPlasmids which express heterologous genes in both plant and animal cells; fusion proteins; gene therapy; high throughput assays; genomics; host cells; animal models
US7794946Feb 4, 1999Sep 14, 2010Life Technologies Corporationkits for detecting antibodies with sensitivity to preferential antigens; generate solid support, join antibodies to support, incubate with antigen, detect bound antigen, recover bound antigen
US7807417Feb 22, 2007Oct 5, 2010Intrexon CorporationEcdysone receptor-based inducible gene expression system
US7811994Apr 13, 2009Oct 12, 2010The Curators Of The University Of MissouriPhage display selection of anti fungal peptides
US7828022May 25, 2007Nov 9, 2010Z CorporationApparatus and methods for handling materials in a 3-D printer
US7829676Sep 3, 2009Nov 9, 2010Intrexon CorporationWhitefly ecdysone receptor antibody
US7851220Nov 2, 2007Dec 14, 2010Intrexon CorporationDiacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7919269Feb 20, 2002Apr 5, 2011Intrexon CorporationWhitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7927788Jun 15, 2007Apr 19, 2011The Hong Kong Polytechnic UniversityBiomarkers for toxic algae
US7932225Dec 23, 2008Apr 26, 2011Pneumrx, Inc.Glue composition for lung volume reduction
US7935510Apr 29, 2005May 3, 2011Intrexon CorporationModulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms
US7971991May 25, 2007Jul 5, 2011Z CorporationApparatus and methods for handling materials in a 3-D printer
US7979152May 25, 2007Jul 12, 2011Z CorporationApparatus and methods for handling materials in a 3-D printer
US7981658Sep 29, 2009Jul 19, 2011RikenNucleic acid molecules, vectors, and host cells encoding fluorescent protein
US7998986Dec 20, 2002Aug 16, 2011Exelixis Patent Company LlcHeterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors
US8012703Jun 23, 2009Sep 6, 2011Life Technologies CorporationMicroarrays and uses therefor
US8013001Dec 17, 2008Sep 6, 2011Exelixis, Inc.Modulators of LXR
US8017055Feb 23, 2010Sep 13, 2011Z CorporationThree-dimensional printer
US8017398Feb 2, 2006Sep 13, 2011Life Technologies CorporationMethod for assaying protein-protein interaction
US8021878Aug 13, 2007Sep 20, 2011Intrexon CorporationRegulatory switches for controlling insect development; biological pest control
US8030066Dec 18, 2006Oct 4, 2011Life Technologies CorporationExpression vector for use in recombinational cloning
US8030067Sep 23, 2010Oct 4, 2011Intrexon CorporationWhitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US8076454Aug 20, 2007Dec 13, 2011Intrexon CorporationModulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms
US8105825Sep 27, 2001Jan 31, 2012Intrexon CorporationMultiple inducible gene regulation system
US8143195Jan 23, 2001Mar 27, 2012Yingjian WangArrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays
US8167395Oct 19, 2010May 1, 20123D Systems, Inc.Apparatus and methods for servicing 3D printers
US8168426Feb 17, 2010May 1, 2012Intrexon CorporationMultiple inducible gene regulation system
US8185229Jun 7, 2011May 22, 20123D Systems, Inc.Apparatus and methods for handling materials in a 3-D printer
US8202718Jun 17, 2010Jun 19, 2012Intrexon CorporationEcdysone receptor-based inducible gene expression system
US8229677Dec 21, 2009Jul 24, 2012Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US8236556Aug 20, 2007Aug 7, 2012Intrexon CorporationMethod of modulating gene expression using an ecdysone receptor-based inducible gene expression system
US8288107Jun 25, 2007Oct 16, 2012Florida State University Research FoundationIncorporating polynucleotides encoding fusion proteins comprising CFTR peptide and DNA binding domain of transcriptional activator that binds to site on detectable gene into host cell ; gene expressing; drug screening, high throughput assay; enhances dimerization of CFTR protein; cystic fibrosis
US8304189Dec 1, 2004Nov 6, 2012Life Technologies CorporationUsing recombination reaction, primer extension and dideoxynucleotides to sequence all or part of a nucleic acid segment
US8318640Apr 8, 2008Nov 27, 2012Danisco Us Inc.Methods for selective targeting
US8399201Oct 31, 2006Mar 19, 2013Janssen Pharmaceutica N.V.Polypeptide complex of TRPM8 and calmodulin and its uses thereof
US8399383May 4, 2001Mar 19, 2013Yale UniversityProtein chips for high throughput screening of protein activity
US8431537Apr 19, 2011Apr 30, 2013Pneumrx, Inc.Glue composition for lung volume reduction
US8497093Aug 16, 2011Jul 30, 2013Intrexon CorporationLeafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US8524948Sep 23, 2011Sep 3, 2013Intrexon CorporationBioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US8546074Jun 14, 2012Oct 1, 2013Massachusetts Institute Of TechnologySir2 activity
US8546090Oct 5, 2012Oct 1, 2013Massachusetts Instittue Of TechnologySIRT4 activities
US8546528Aug 3, 2009Oct 1, 2013Danisco Us Inc.Skin or hair binding peptides
US8598409Aug 24, 2007Dec 3, 2013Intrexon CorporationNon-human organism comprising a gene expression modulation system encoding a chimeric retinoid X receptor
US8637264 *Jun 30, 2011Jan 28, 2014Life Technologies CorporationMicroarrays and uses therefor
US8642284Dec 13, 2000Feb 4, 2014Massachusetts Institute Of TechnologyMethods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US8652797Sep 12, 2008Feb 18, 2014Massachusetts Institute Of TechnologyMethods of NAD-dependent deacetylation of a lysine residue in a protein
US8669051Aug 20, 2007Mar 11, 2014Intrexon CorporationSubstitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US8669072Aug 13, 2007Mar 11, 2014Intrexon CorporationOxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US8680249Sep 7, 2007Mar 25, 2014Intrexon CorporationLeafthopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US8691527Aug 20, 2007Apr 8, 2014Intrexon CorporationSubstitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US8691730Sep 12, 2008Apr 8, 2014Adimab, LlcRationally designed, synthetic antibody libraries and uses therefor
US8691944Oct 4, 2006Apr 8, 2014The Research Foundation For The State University Of New YorkFibronectin polypeptides and methods of use
US8709416Dec 20, 2011Apr 29, 2014Amplimmune, Inc.Compositions of PD-1 antagonists and methods of use
US8715959Feb 20, 2002May 6, 2014Intrexon CorporationSubstitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US8728808Mar 27, 2012May 20, 2014Intrexon CorporationMultiple inducible gene regulation system
US20120004131 *Jun 30, 2011Jan 5, 2012Life Technologies CorporationMicroarrays and uses therefor
USH1892 *Jul 19, 1996Oct 3, 2000Pharmacia And Upjohn CompanyHigh volume nutrient based yeast two-hybrid assay for the identification of specific protein:protein interacting inhibitors
CN1303218C *Dec 19, 2003Mar 7, 2007中国科学院上海药物研究所Method of screening peroxisome proliferator-activated receptor antagon and agonist
DE19502584A1 *Jan 27, 1995Aug 3, 1995Medigene GmbhDetection method for at least one regulatory factor
DE19502584C2 *Jan 27, 1995Aug 12, 1999Medigene Ag Ges Fuer MolekularVerfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
DE102010056289A1Dec 24, 2010Jun 28, 2012Geneart AgVerfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
EP0677115A1 *Oct 7, 1994Oct 18, 1995Dana Farber Cancer InstituteTia-1 binding proteins and isolated complementary dna encoding the same
EP0750630A1 *Mar 13, 1995Jan 2, 1997Ariad Pharmaceuticals, Inc.Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
EP0830459A1 *Apr 11, 1996Mar 25, 1998The General Hospital CorporationReverse two-hybrid systems
EP1007689A2 *Jul 10, 1998Jun 14, 2000Kosan BiosciencesProduction of polyketides in plants
EP1017980A2 *Mar 12, 1997Jul 12, 2000Smithkline Beecham CorporationMethods of the identification of pharmaceutically active compounds
EP1097993A2 *Nov 3, 2000May 9, 2001Secretary of Agency of Industrial Science and TechnologyFunctional ribozyme chimeric molecules capable of sliding
EP1241265A2 *Apr 25, 1997Sep 18, 2002Massachusetts Institute Of TechnologyScreening assay for small ligands
EP1958966A2Jun 30, 1995Aug 20, 2008Dana-Farber Cancer InstituteMethods for modulating T cell responses by manipulating a common cytokine receptor gamma chain
EP1964921A2Jun 21, 2000Sep 3, 2008Oscient Pharmaceuticals CorporationThe high bone mass gene of 11q13.3
EP1967525A2May 8, 2002Sep 10, 2008Darwin Molecular CorporationA method for regulating immune function in primates using the foxp3 protein
EP1988165A1Mar 31, 2000Nov 5, 2008The University of North Carolina at Chapel HillIsolated DNA encoding cullin regulator ROC1, isolated proteins encoded by the same, and methods utilizing the same
EP1990413A1Nov 2, 2000Nov 12, 2008Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Screening method for candidate drugs
EP2014674A1Nov 26, 2002Jan 14, 2009CellvirProtein-protein interactions in human immunodeficiency virus
EP2033972A1Nov 2, 2000Mar 11, 2009Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V.Screening method for candidate drugs
EP2105496A1Dec 7, 2001Sep 30, 2009Life Technologies CorporationMethods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP2246363A1Nov 17, 2003Nov 3, 2010Novartis Vaccines and Diagnostics, Inc.Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2275558A2Feb 20, 2002Jan 19, 2011Intrexon CorporationNovel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP2287192A1Nov 17, 2003Feb 23, 2011Novartis Vaccines and Diagnostics, Inc.Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2292088A1May 2, 2005Mar 9, 2011Intrexon CorporationMutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP2305824A1Sep 28, 2001Apr 6, 2011Intrexon CorporationMultiple inducible gene regulation system
EP2316951A1Jan 17, 2002May 4, 2011Trubion Pharmaceuticals, Inc.Binding domain-immunoglobulin fusion proteins
EP2322933A1Aug 29, 2002May 18, 2011Pacific Northwest Research InstituteDiagnosis of carcinomas
EP2340709A1Apr 24, 2002Jul 6, 2011Johns Hopkins UniversityUse of follistatin to increase muscle mass
EP2360259A2Jul 26, 2001Aug 24, 2011The Johns Hopkins University School Of MedicinePromyostatin peptides and methods of using same
EP2365003A1Apr 11, 2009Sep 14, 2011Emergent Product Development Seattle, LLCCD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2374891A2Feb 20, 2002Oct 12, 2011Intrexon CorporationChimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
EP2392561A1Jul 5, 2003Dec 7, 2011Intrexon CorporationAlpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
EP2420576A2Jan 4, 2007Feb 22, 2012Fujirebio America, Inc.Use of HE4 and other biochemical markers for assessment of ovarian cancers
EP2423321A2Jan 4, 2007Feb 29, 2012Fujirebio America, Inc.Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers
EP2436766A1 *Sep 29, 2010Apr 4, 2012Deutsches KrebsforschungszentrumMeans and methods for improved protein interaction screening
EP2455375A2Feb 10, 2004May 23, 2012Intrexon CorporationDiacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
EP2460786A1Feb 27, 2004Jun 6, 2012Intrexon CorporationBioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
EP2463269A1Feb 27, 2004Jun 13, 2012Intrexon CorporationBioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
EP2581383A1Nov 12, 2003Apr 17, 2013Genencor International, Inc.Skin or hair binding peptides
EP2662383A1Aug 25, 2009Nov 13, 2013Amplimmune, Inc.PD-I antagonists and methods for treating infectious disease
EP2706116A1Jan 17, 2002Mar 12, 2014Emergent Product Development Seattle, LLCBinding domain-immunoglobulin fusion proteins
WO1995009924A1 *Oct 7, 1994Apr 13, 1995Dana Farber Cancer Inst IncTia-1 binding proteins and isolated complementary dna encoding the same
WO1995029195A1 *Apr 7, 1995Nov 2, 1995California Inst Of TechnUbiquitin-based split protein sensor
WO1995032225A1 *May 23, 1995Nov 30, 1995Salk Inst For Biological StudiMethod for site-specific integration of nucleic acids and related products
WO1995034646A1 *May 31, 1995Dec 21, 1995American Cyanamid CoNovel cell systems having specific interaction of peptide binding pairs
WO1996002561A1 *Jul 20, 1995Feb 1, 1996Gen Hospital CorpInteraction trap systems for detecting protein interactions
WO1996003501A1 *Jul 12, 1995Feb 8, 1996Ciba Geigy AgDual hybrid system
WO1996023899A1 *Jul 27, 1995Aug 8, 1996Univ Massachusetts MedicalMethods of selecting a random peptide that binds to a target protein
WO1996029429A1 *Oct 13, 1995Sep 26, 1996Wisconsin Alumni Res FoundSystem to detect protein-rna interactions
WO1996032503A1 *Apr 11, 1996Oct 17, 1996Gen Hospital CorpReverse two-hybrid systems
WO1996035804A1 *May 3, 1996Nov 14, 1996Bramhill DavidA novel biochemical interaction in bacteria
WO1997006277A1 *Aug 9, 1996Feb 20, 1997Univ CaliforniaMethods for drug screening
WO1997009418A1 *Jul 24, 1996Mar 13, 1997Salk Inst For Biological StudiTranscriptional co-repressor that interacts with nuclear hormone receptors and uses therefor
WO1997014038A1 *Oct 10, 1996Apr 17, 1997Terrapin Tech IncMethods to identify modulators of cell signaling
WO1997024457A1 *Dec 30, 1996Jul 10, 1997Guilford Pharm IncMethod and kit for detection of multiple protein interactions
WO1997038127A1 *Apr 9, 1997Oct 16, 1997Gen Hospital CorpInteraction trap systems for detecting protein interactions
WO1997041255A1 *Apr 25, 1997Nov 6, 1997Massachusetts Inst TechnologyThree-hybrid screening assay
WO1997045745A1 *May 23, 1997Dec 4, 1997Amersham Int PlcEx vivo/in vitro assay systems
WO1998001579A1 *Jun 25, 1997Jan 15, 1998Centre Nat Rech ScientSystem for detecting protein-protein interactions
WO1998003676A1 *Jul 17, 1997Jan 29, 1998Hagenmaier Hans PaulProcess for detecting effectors of intra- and/or intercellular protein-protein interactions
WO1998007845A1 *Aug 22, 1997Feb 26, 1998Dove SimonInteraction trap assay, reagents and uses thereof
WO1998013502A2 *Sep 26, 1997Apr 2, 1998Icos CorpMethod to identify compounds for disrupting protein/protein interactions
WO1998016835A2 *Oct 3, 1997Apr 23, 1998Terrapin Tech IncSystem to detect small molecule/peptide interaction
WO1998039483A1 *Feb 27, 1998Sep 11, 1998Ventana Genetics IncMethods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
WO1998046789A1 *Apr 15, 1998Oct 22, 1998Cormack RobertNew reporter-vectors for one-hybrid and two-hybrids systems
WO1998056907A1 *Jun 15, 1998Dec 17, 1998Horst DomdeyHeart and skeleton muscle specific nucleic acid, the production and use thereof
WO1998056910A1 *Jun 11, 1998Dec 17, 1998Chiron CorpDETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE
WO1999001473A2 *Jul 3, 1998Jan 14, 1999David William HoldenAnti-bacterial methods and materials
WO1999002669A2 *Jul 10, 1998Jan 21, 1999Kosan Biosciences IncProduction of polyketides in plants
WO1999010376A1 *Aug 14, 1998Mar 4, 1999Univ WashingtonInducible regulatory system and use thereof
WO1999010532A1 *Aug 24, 1998Mar 4, 1999Junko MizukamiMethods for identifying or screening agonists for and antagonists to ppar
WO1999042612A1 *Feb 17, 1999Aug 26, 1999Micheline FromontA fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
WO2000029565A1 *Nov 17, 1999May 25, 2000ArcarisMethods for validating polypeptide targets that correlate to cellular phenotypes
WO2001081548A1 *Apr 23, 2001Nov 1, 2001American Home ProdNovel cell systems having specific interaction of peptide binding pairs
WO2002029417A2 *Oct 4, 2001Apr 11, 2002Odyssey Pharmaceuticals IncDynamic visualization of expressed gene networks in living cells
WO2002066612A2Feb 20, 2002Aug 29, 2002Rohm & HaasNovel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
WO2002070663A2 *Mar 5, 2002Sep 12, 2002Pe Corp NyIsolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2003002723A2 *Jul 1, 2002Jan 9, 2003Myriad Genetics IncMating-based method for detecting protein-protein interaction
WO2003018777A1 *Aug 23, 2002Mar 6, 2003Univ CaliforniaA universal light-switchable gene promoter system
WO2004001378A2 *Jun 20, 2003Dec 31, 2003James E HopperMethods for protein analyses and protein expression in multicellular organisms and cells therefrom
WO2004072254A2Feb 10, 2004Aug 26, 2004Rheogene Holdings IncDiacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
WO2005014638A2 *Aug 4, 2004Feb 17, 2005Richard BennettNovel peptide interacting with anti-apoptotic proteins of a bcl-2 family
WO2005017148A1Dec 24, 2003Feb 24, 2005Martha S Hayden-LedbetterBinding constructs and methods for use thereof
WO2006017279A2 *Jul 12, 2005Feb 16, 2006Ding ZhiyongMethods and compositions related to identifying protein-protein interactions
WO2007002559A1Jun 26, 2006Jan 4, 2007Exelixis IncPyrazole based lxr modulators
WO2011026122A2Aug 31, 2010Mar 3, 2011Amplimmune, Inc.B7-h4 fusion proteins and methods of use thereof
WO2011026132A2Aug 31, 2010Mar 3, 20111/3Acamplimmune, Inc.Methods and compositions for the inhibition of transplant rejection
WO2011045166A1Sep 24, 2010Apr 21, 2011INSERM (Institut National de la Santé et de la Recherche Médicale)Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011079308A2Dec 23, 2010Jun 30, 2011Emergent Product Development Seattle, LlcCompositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2011090754A1Dec 29, 2010Jul 28, 2011Emergent Product Development Seattle, LlcPolypeptide heterodimers and uses thereof
WO2011090761A1Dec 29, 2010Jul 28, 2011Emergent Product Development Seattle, LlcRon binding constructs and methods of use thereof
WO2011090762A1Dec 29, 2010Jul 28, 2011Emergent Product Development Seattle, LlcHeterodimer binding proteins and uses thereof
WO2011119956A1Mar 25, 2011Sep 29, 2011Integratech Proteomics, LlcControlled release hybrid systems
WO2011138671A2Apr 20, 2011Nov 10, 2011Universite Rene Descartes - Paris 5Tubby-like protein isoforms and their applications
WO2012001647A2Jun 30, 2011Jan 5, 2012Compugen Ltd.Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2012035518A1Sep 16, 2011Mar 22, 2012Compugen Ltd.Compositions and methods for treatment of drug resistant multiple myeloma
WO2012041802A1 *Sep 26, 2011Apr 5, 2012Deutsches KrebsforschungszentrumMeans and methods for improved protein interaction screening
WO2012084923A1Dec 20, 2011Jun 28, 2012Geneart AgMethod for producing reading-frame-corrected fragment libraries
WO2012156476A2May 16, 2012Nov 22, 2012INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for screening substances capable of modulating the replication of an influenza virus
WO2013037482A1Sep 11, 2012Mar 21, 2013Phenex Pharmaceuticals AgFarnesoid x receptor agonists for cancer treatment and prevention
WO2014053871A1Oct 4, 2012Apr 10, 2014INSERM (Institut National de la Santé et de la Recherche Médicale)A method for screening a compound capable of inhibiting the notch1 transcriptional activity
Classifications
U.S. Classification435/6.13
International ClassificationC12N15/10, C12Q1/68
Cooperative ClassificationC12N15/1055, C12Q1/6897
European ClassificationC12N15/10C6, C12Q1/68P
Legal Events
DateCodeEventDescription
Aug 1, 2005FPAYFee payment
Year of fee payment: 12
Feb 1, 2001FPAYFee payment
Year of fee payment: 8
Feb 3, 1997FPAYFee payment
Year of fee payment: 4
Jan 24, 1990ASAssignment
Owner name: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YOR
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:FIELDS, STANLEY;SONG, OK-KYU;REEL/FRAME:005225/0567
Effective date: 19900119